Company Overview and News

 
SHG / Shinhan Financial Group Co., Ltd. 6-K. SUMMARY OF FY2018 1H BUSINESS REPORT (Current Report of Foreign Issuer)

2018-08-14 sec.gov
shg-6k_20180814.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SHG

 
SHG / Shinhan Financial Group Co., Ltd. 6-K. SHINHAN FINANCIAL GROUP 2018 1H OPERATING RESULTS (Current Report of Foreign Issuer)

2018-07-24 sec.gov
shg-6k_20180724.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SHG

 
SHG / Shinhan Financial Group Co., Ltd. 6-K. SHINHAN FINANCIAL GROUP 2018 1H BUSINESS RESULTS (Current Report of Foreign Issuer)

2018-07-17 sec.gov
shg-6k_20180717.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SHG

135
20 Stocks With Renewed Bull Cases After Trump-Kim Summit

2018-06-13 investorplace - 1
The importance of President Donald Trump’s recent meeting with North Korean dictator Kim Jong Un cannot be overstated. For the first time in history, a sitting U.S. President met face-to-face with the hermit nation’s leader. Not only that, the entire world at least temporarily spares itself the prospect of all-out nuclear war.
LMT KWHIF KEP CAT SKM PKX KTOS KT TWTR 8306 6367 7012 MBFJF SHG DKILY SKMD KB HYUO CATR HXSCF KWHIY WF HYUD DKILF KMTUF LPL JPM MUFG RTN HYUP MTU HXSCL

1
SHG / Shinhan Financial Group Co., Ltd. 6-K. FY2018 1Q BUSINESS REPORT (Current Report of Foreign Issuer)

2018-05-15 sec.gov - 1
shg-6k_20180515.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
SHG

1
SHG / Shinhan Financial Group Co., Ltd. FORM 20-F

2018-04-30 sec.gov - 1
Form 20-F Table of Contents As filed with the Securities and Exchange Commission on April 30, 2018
SHG

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to SHG / Shinhan Financial Group Co., Ltd. on message board site Silicon Investor.

Joshua Gold Resources (JSHG) Joshua Gold Resources (JSHG) Joshua Gold Resources (JSHG) USHG / Ionatron USHG / Ionatron USHG / Ionatron
USHG: U.S. Home u0026 Garden, Inc. USHG: U.S. Home u0026 Garden, Inc. USHG: U.S. Home u0026 Garden, Inc. CashGuard CashGuard CashGuard
USHG - Anyone know Estimated earnings? USHG - Anyone know Estimated earnings? USHG - Anyone know Estimated earnings? SHGE is symbol for SUN HEALTHCARE GROUP SHGE is symbol for SUN HEALTHCARE GROUP SHGE is symbol for SUN HEALTHCARE GROUP
Sun Healthcare [SHG] Sun Healthcare [SHG] Sun Healthcare [SHG]
CUSIP: 824596100